Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sufentanil NanoTab Clear all
Completed Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

NCT01539642
View directory record Official record
Conditions
Post-Operative Pain
Interventions
Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Mobile, Alabama • Laguna Hills, California • Stamford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Sep 24, 2026, 12:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Delivery Route on PK of Sufentanil NanoTab

NCT01639729
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Treatment A: Sufentanil IV, Treatment B: Sufentanil NanoTab Sublingual, Treatment C: Sufentanil NanoTab Buccal, Treatment D: Sufentanil NanoTab Oral
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 24, 2026, 12:08 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

NCT01539538
View directory record Official record
Conditions
Post-Operative Pain
Interventions
Sufentanil NanoTab PCA System/15 mcg, morphine IV PCA
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
16
States / cities
Florence, Alabama • Montgomery, Alabama • Sheffield, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 24, 2026, 12:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

NCT01660763
View directory record Official record
Conditions
Post Operative Pain
Interventions
Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Damascus, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Sep 24, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain

NCT00833040
View directory record Official record
Conditions
Cancer, Pain
Interventions
Sublingual sufentanil NanoTabs™ and placebo NanoTabs™
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Montebello, California • Jacksonville, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Sep 24, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement

NCT00612534
View directory record Official record
Conditions
Post Operative Pain
Interventions
Sufentanil NanoTab, Placebo NanoTab
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
45 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Sep 24, 2026, 12:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

NCT01761565
View directory record Official record
Conditions
Plasma Concentrations
Interventions
Single dose of SUF NT 15 mcg, 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 24, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement

NCT00859313
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Sufentanil NanoTab PCA System/15 mcg
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
45 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Birmingham, Alabama • Vero Beach, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Sep 24, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

NCT01710345
View directory record Official record
Conditions
Acute Pain
Interventions
Sufentanil NanoTab 20 mcg, Sufentanil NanoTab 30 mcg, Placebo NanoTab
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Pasadena, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 24, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

NCT00894699
View directory record Official record
Conditions
Sedation, Anxiety, Pain
Interventions
Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03), Placebo NanoTab™
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Sep 24, 2026, 12:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

NCT01721070
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Sufentanil NanoTab (SUF NT) 15 mcg, Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Sep 24, 2026, 12:08 PM EDT